Shots:
- NovaRock to receive $7.5M up front and is eligible to receive ~$633M as development & sales milestones along with royalties on the sales of the licensed products in the Territory
- Flame gets the exclusive rights to NBL-015 for pancreatic and gastric cancer outside of Greater China including mainland China, Hong Kong, Macau, and Taiwan & will lead the development, regulatory approval & commercialization of NBL-015
- The companies collaborated to develop the two CD137 bispecific Ab programs by using NovaRock’s NovaTE technology. The products are expected to be entered into clinical development in late 2023
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post NovaRock Signs an Exclusive License Agreement with Flame to Co-Develop and Commercialize NBL-015 first appeared on PharmaShots.
